Bulgária - búlgaro - Изпълнителна агенция по лекарствата

mundipharma gesellschaft m.b.h. - 50 micrograms/5 micrograms per actuation pressurised inhalation, suspension

Bulgária - búlgaro - Изпълнителна агенция по лекарствата

mundipharma gesellschaft m.b.h. - 125 micrograms/5 micrograms per actuation pressurised inhalation, suspension

Bulgária - búlgaro - Изпълнителна агенция по лекарствата

mundipharma gesellschaft m.b.h. - 250 micrograms/10 micrograms per actuation pressurised inhalation, suspension

Bulgária - búlgaro - Изпълнителна агенция по лекарствата

glaxo group ltd. - Салбутамол - 100 micrograms/metered actuation, pressurised inhalation suspension

Bulgária - búlgaro - Изпълнителна агенция по лекарствата

glaxo group ltd. - Флутиказона пропионат - 50 micrograms/metered actuation, nasal spray, suspension

Bulgária - búlgaro - Изпълнителна агенция по лекарствата

ГлаксоСмитКлайн ЕООД - Салметерол - 25 micrograms/metered actuation,pressurised inhalation, suspension

Bulgária - búlgaro - Изпълнителна агенция по лекарствата

80 mg/5 mg tablets

Bulgária - búlgaro - Изпълнителна агенция по лекарствата

80 mg/10 mg tablets

União Europeia - búlgaro - EMA (European Medicines Agency)

alexion europe sas - себелапаза алфа - Липиден метаболизъм, вродени грешки - Други стомашно-чревния тракт и обмяната на веществата средства, - kanuma е показан за дългосрочна ензимна заместителна терапия (ert) при пациенти на всички възрасти с дефицит на лизозомална киселина липаза (lal).

União Europeia - búlgaro - EMA (European Medicines Agency)

alexion europe sas - ravulizumab - Хемоглобинурия, пароксизма - Селективни имуносупресори - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.